Brief: Kuros Biosciences Receives FDA Clearance For Extending Commercial Indications Of Magnetos Putty
Dec 10 (Reuters) - Kuros Biosciences AG KURN.S :
* KUROS RECEIVES FDA 510(K) CLEARANCE FOR EXTENDING
COMMERCIAL
INDICATIONS OF MAGNETOS PUTTY IN UNITED STATES
* PAVES WAY FOR COMMERCIAL EXPANSION INTO MORE CLINICAL
INDICATIONS IN ORTHOPEDIC SURGERY
Further company coverage: KURN.S
(Reporting by Riham Alkousaa)
((Riham.Alkousaa@thomsonreuters.com;))
Recent news on Kuros Biosciences AG
See all newsSwitzerland's Kuros Biosciences swing to H1 profit as revenue jumps
Brief: Kuros Biosciences H1 Gross Profit USD 79.965 Million
Europe Research Roundup: Avanza Bank, Forvia, Novonesis
Switzerland's Kuros Biosciences 2025 total medical device revenue rises, helped by MagnetOs growth
Brief: Kuros Biosciences FY Net Income USD 2.462 Million